Keywords
Cholesterol
Triglycerides
Metabolic syndrome
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Analyze the evolution of the lipid profile and associated risk factors in patients with dyslipidemia and the use of Antiretroviral Therapy for better management of patients. Methods: Descriptive-longitudinal study in people living with HIV and regularly using ART with a diagnosis of dyslipidemia, assessing lifestyle habits and risks for metabolic syndrome. Results: Fifty-eight patients were evaluated, with the distribution between male and female gender being equivalent, mean age 58.1 years and mean time of infection with the virus 15.68 years, with a maximum of 32 years. The average time using ART was 14.94 years, with the use of Protease Inhibitors being prevalent. It was observed that there was an increase in HDL-cholesterol and a decrease in LDL-cholesterol, total cholesterol and triglycerides. When analyzing the comorbidities related to the condition, 77.5% had metabolic syndrome according to the IDF criteria,43% of patients were diagnosed with high blood pressure and 73.6% had diabetes. All patients were using lipid-lowering drugs. Conclusion: Improvement in the lipid profile was observed, however, exposure to multiple behavioral and health factors impact endocrine-metabolic control.
References
ACHILA OO, et al. Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea. PLOS ONE, 2022; 17: 0270838.
ANASTOS K, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr. 2007; 45: 34–42.
BHAGWAT P, et al. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. Oxford University Press on behalf of Infectious Diseases Society of America, 2018; 5: 201.
BRASIL. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Manejo da Infecção pelo HIV em adultos. Brasília (DF): Ministério da Saúde, 2018.
CARR A e COOPER DA. Adverse effects of antiretroviral therapy. Lancet, 2000; 356: 1423-30.
COSTA C, et al. Associação entre fatores sociodemográficos e comportamentais com a síndrome metabólica em pessoas vivendo com HIV. Rev Gaúcha Enferm. 2019; 40: 20180379.
Da CUNHA GH, et al. Diabetes mellitus in people living with HIV/AIDS: prevalence and associated risk factors. AIDS Care-Psychol Social-Medical Asp AID/HIV, 2020; 32: 600-607.
FRIIS-MØLLER N, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the dad study. Aids, 2003; 17: 1179-1193.
FALUDI AA, et al; Sociedade Brasileira de Cardiologia. Atualização da Diretriz Brasileira e Prevenção da Aterosclerose. Arq Bras Cardiol, 2017;109: 33.
FARHI L, et al. Dislipidemia em pacientes HIV/AIDS em uso de antirretrovirais num hospital universitário, Rio de Janeiro, Brasil. J Bras Patol Med Lab, 2008; 44 (3): 175-184.
GUIMARÃES N, et al. Alterações metabólicas e estimativa de risco cardiovascular em pessoas vivendo com HIV/AIDS doze meses após o início da TARV. Revista Médica de Minas Gerais, 2017; 27: 1859.
GRUNDY S M, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005; 112(17): 285-290.
HAMILTON D, et al. Rosuvastatina e Ciprofibrato no Tratamento da Dislipidemia em Pacientes com HIV. Arq Bras Cardiol, 2012; 99(5): 997-1007.
IDF. INTERNATIONAL DIABETES FEDERATION (BE). The IDF consensus worldwide definition of the metabolic syndrome. Brussels: IDF; 2006.
KÖSE E, et al. Bibliometric Analysis of HIV and Exercise Literature based on Scientific Studies from 1990-2020. Iran J Public Health, 2021; 50: 2397-2410.
KRAMER AS, et al. Alterações metabólicas, terapia antirretroviral e doença cardiovascular em idosos portadores de HIV. Arq Bras Cardiol, 2009; 93: 561–8.
LAZZARETTI RK, et al. Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1–Infected Individuals A Randomized Trial. Journal of the American College of Cardiology, 2012; 12: 980-988.
LIMA MA, et al. Hipertensão Arterial Sistêmica em Pessoas Vivendo Com HIV/AIDS: Revisão Integrativa. Rev Bras Enferm, 2017; 70: 1379-88.
MARQUES SC, et al. Avaliação da qualidade de vida de pessoas vivendo com HIV/AIDS: revisão integrativa. Revista Enfermagem UERJ, 2020; 28: 39144.
MARTINI S, et al. Dynamics of Lipid Profile in Antiretroviral-Naïve HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study. Biomedicines, 2022; 10: 3164.
MENSINK RP, et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-1155.
Nakazone M, et al. Prevalência de Síndrome Metabólica em Indivíduos Brasileiros Pelos Critérios NCEP-ATPIII e IDF. Rev Assoc Med Bras, 2007; 53: 407-13.
NEUHAUS J, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010 Jun 15; 201: 1788–1795.
NEW-AARON M, et al. Pancreatogenic Diabetes: Triggering Effects of Alcohol and HIV. Biology, 2021; 10: 108.
NOUBISSI EC, et al. Diabetes and HIV. Curr Diab Rep, 2018; 18: 1-8.
O'CLEIRIGH C, et al. Integrated Treatment for Smoking Cessation, Anxiety, and Depressed Mood in People Living With HIV: A Randomized Controlled Trial. J Acquir Immune Defic Syndr, 2018; 79: 261–268.
OUYANG J, et al. Metformin effect on gut microbiota: insights for HIV- related inflammation. AIDS Res Ther, 2020; 17: 1-9.
PALLIPAMU N, et al. A Systematic Review of How To Reduce Morbidity in HIV Patients With Cardiovascular Diseases. Cureus, 2023; 15(2): 34745.
PAPANTONIOU E, et al. Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas. Life, 2024; 14: 449.
POLACOW VO e LANCHA AH. Dietas Hiperglicídicas: Efeitos da Substituição Isoenergética de Gordura por Carboidratos Sobre o Metabolismo de Lipídios, Adiposidade Corporal e Sua Associação com Atividade. Arq Bras Endocrinol Metab, 2007; 53: 389-400.
PONTES-PEREIRA PS, et al. Prevalência de doenças crônicas não transmissíveis em pessoas vivendo com HIV. Acta Paul Enferm, 2023; 36: APE01132.
SAMUEL SB, et al. Obesity and weight gain in persons with HIV. Curr HIV/AIDS Rep, 2020; 17: 138–15.
SANTOS R, et al. Prevalência de dislipidemia e sua relação com condições sociodemográficas, de saúde e de comportamento entre usuários da atenção primária à saúde. Brazilian Journal of Health Review, 2022; 5: 7353-7370.
SILVA LS e SOUZA PG. Ação dos antirretrovirais em portadores de HIV: relação de uma classe de fármaco com o surgimento de dislipidemias. Brazilian Journal of Development, 2020; 6: 37620-37635.
SILVERBERG MJ, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med, 2009; 150: 301-13.
STEIN JH, et al. Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients. Circulation, 2008; 118: 54-60.